Rifapentine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Rifapentine
Rifapentine.svg
Systematic (IUPAC) name
(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z,26E)-26-{[(4-cyclopentylpiperazin-1-yl)amino]methylidene}-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a602026
Legal status ?
Pharmacokinetic data
Bioavailability increases when administered with food
Identifiers
CAS number 61379-65-5 YesY
ATC code J04AB05
PubChem CID 5462354
DrugBank DB01201
ChemSpider 10482075 YesY
UNII XJM390A33U YesY
KEGG D00879 YesY
ChEBI CHEBI:45304 YesY
ChEMBL CHEMBL1660 YesY
NIAID ChemDB 007686
Synonyms 3{[(4-cyclopentyl-1-piperazinyl)imino]methyl}rifamycin
Chemical data
Formula C47H64N4O12 
Mol. mass 877.031 g/mol
 YesY (what is this?)  (verify)

Rifapentine (INN, marketed under the brand name Priftin by Sanofi-Aventis) is an antibiotic drug used in the treatment of tuberculosis.

Medical uses[edit]

A review of alternative regimens for prevention of active tuberculosis in HIV-negative individuals with latent TB found that a weekly, directly observed regimen of rifapentine with isoniazid for three months was as effective as a daily, self -administered regimen of isoniazid for nine months. But the rifapentine-isoniazid regimen had higher rates of treatment completion and lower rates of hepatotoxicity. However, the rate of treatment-limiting adverse events was higher in the rifapentine-isoniazid regimen. [1]

History[edit]

Rifapentine was first synthesized in 1965 by the same company that produced rifampin. The drug was approved by the Food and Drug Administration (FDA) in June 1998. It is synthesized in one step from rifampicine.

See also[edit]

References[edit]

  1. ^ Sharma SK et al . (2013). "Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.". Cochrane Database of Systematic Reviews 7. doi:10.1002/14651858.CD007545.pub2. PMID 23828580.